Dr. Gianella is the executive director of the Last Gift Study, and she oversees all procedures related to recruitment, outreach, participant enrollment, and follow up. She is involved in the development of the rapid research autopsy procedures and the creation of lab-based techniques to process blood and tissues in an effort to characterize HIV reservoirs.
Dr. Kallas directs the clinical and community engagement efforts for the HOPE Collaboratory in Sao Paulo, Brazil.
University of Sao Paulo School of Medicine
Hannah Kibuuka, MBchB, MMed, MPH
Makerere University Walter Reed Project
Dr. Kibuuka brings tremendous clinical trials experience plus HIV cohort study leadership and as a co-investigator, she participates in all procedures related to recruitment, outreach, participant enrollment, and follow up.
As part of HOPE, Dr. Kumar will direct a research program for targeting nucleic-acid editing/modifying molecules to HIV-infected cells for suppressing viral reactivation and excising provirus and direct studies in humanized mouse models of HIV infection and latency
Ulrike Lange, MD, PhD
Heinrich Pette Institute – Leibniz Institute of Experimental Virology and University Medical Center Hamburg-Eppendorf
Dr. Lange contributes her expertise on chronic HIV infection to provide cellular models of clinical relevance to test newly developed therapeutic strategies developed in HOPE.
Dr. Mwesigwa is the site principal investigator for the MUWRP study that collects biospecimens for the characterization of HIV reservoirs in different body compartments and oversees all procedures related to recruitment, community outreach, participant enrollment, and follow up for the HOPE study.
Dr. Ndhlovu research program is dedicated to confronting the challenges of HIV and aging using immuno-epigenetic approaches to resolve molecular mechanisms of HIV age related complications and viral persistence.
Doug Nixon, MD, PhD
Weill Cornell Medicine
New York, NY
Dr. Nixon's group will be working closely with Cedric Feschotte and his team to learn how HERVs may give clues to locking HIV.
Melanie Ott, MD, PhD
San Francisco, CA
Dr. Ott is the Program Director for HOPE. Her work focuses on the role of reversible protein acetylation in HIV transcription and identifying molecular mechanisms controlling viral latency.
Nadia Roan, PhD
San Francisco, CA
Dr. Roan will investigate the mechanisms underlying transcriptional silencing of the HIV provirus, and the host features that prevent “block and lock” after a variety of therapeutic interventions.
Pauline Sameshima, PhD
Thunder Bay, Ontario, Canada
Dr. Sameshima will work on developing cure curriculum and education through community arts integrated research.